Globus Medical Inc. (GMED) Revenue-to-Profit Sankey Flow & SEC XBRL Financials
Globus Medical Inc. (GMED) receives a Roarable Rating of D+ (Sell) and flashes a Red SELL / AVOID warning (68/100 RQD Confidence). Our SEC filing scanner spotted paper earnings outpacing real operating cash flow (+175.3% (NI vs OCF)) while unpaid customer invoices grew—a classic sign to step aside until cash flow catches up.
How GMED Turns Every Dollar of Sales Into Real Bottom-Line Profit
Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory
| Fiscal Year | Revenue | Gross Margin | Op Margin | Net Profit | Free Cash Flow | ROIC % |
|---|---|---|---|---|---|---|
| FY 2025 | $2.94B | 67.4% | 16.3% | $537.9M | $588.8M | 8.7% |
| FY 2024 | $2.52B | 58.9% | 6.6% | $103.0M | $405.2M | 3.4% |
| FY 2023 | $1.57B | 44% | 8.5% | $122.9M | $172.9M | 2.8% |
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring GMED)
- ✓Live walkthrough of GMED's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
GMED Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +16.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on GMED today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for GMED. Explore sector supply chains on /butterfly.
GMED Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDHow profitable is Globus Medical Inc. (GMED)?
In FY 2025 (10-K), GMED converted $2.9B of revenue into a 67.4% gross margin, 16.3% operating margin, and $588.8M in free cash flow (20% FCF margin).